Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Apr
12
Today In Oncology
Pausing vs Continuing BTK Inhibitors at Time of COVID 19 Vaccination in Patients With CLL
Neoantigen-Selected TILs Boost Response to Immunotherapy in Heavily Pretreated GI Cancers
Low-Dose vs Regular-Dose Apixaban for Prevention of VTE Recurrence in Patients With Cancer
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC
Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo